Summary Aim: PankoMab is a novel antibody that recognizes a tumor-specific epitope of Mucin 1 (MUC1). The aim of this study was the evaluation of PankoMab as a potential diagnostic tool and its comparison with two established antibodies against MUC1 in human ductal breast cancer. Materials and Methods: Breast carcinomas were obtained from 82 patients. MUC1 expression and hormone receptor status were determined by immunohistochemistry of paraffin-embedded material. Results: PankoMab revealed strong correlation to hormone receptor expression. DF3 showed no correlation with grading, lymph node involvement and/or estrogen receptor (ER) expression. In the subgroup of lymph node-positive and ER-negative tumors, we saw a significantly reduced DF3 staining in G3 tumors compared to G2 tumors. VU-4-H5 showed increased staining intensity in correlation with increased grading. In addition, we also identified a significantly higher expression of the VU-4-H5 epitope in lymph node-positive carcinomas compared to carcinomas without lymph node involvement. Conclusion: PankoMab revealed strong correlation to hormone receptor expression in ductal carcinoma of the breast. VU-4-H5 showed increased staining intensity in correlation with increased grading and lymph node involvement. PankoMab and VU-4-H5 staining could be a useful combination in ductal breast cancer prognosis by immunohistochemistry.
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Introduction
Mucinderivesfromthewordmucusanddesignatesthestructuralcomponentofit.TheO-glycansexhibithighwater-binding capacity on the mucins, protect the central protein from proteolysisandareinvolvedinantigenbindingand/orsignal transduction [1, 2] .Mucinsaredividedintotwogroups:membrane-bound mucins such as Mucin 1 (MUC1) and secreted mucins.
MUC1(alsonamedCD227,EMA,PAS-O,PEM,MAM-6,orepisialin)playsaroleinthebarrierfunctionofthemucous membranes and helps to regulate cell adhesion. The chromosomallocalizationwasdefinedas1q21 [3] .Itisahighmolecular-weight transmembrane glycoprotein with unique properties.Itisextremelylonganditsstretchedextracellular partconsistsofidenticalrepeatsofa20-aminoacidpeptide, the number of which varies in the population. The repeats are heavily O-glycosylated, with characteristic short glycan chains.Thiscanbemonitoreddirectlywithmonoclonalantibodies(mAbs)totheglycansaswellasindirectlywithmAbs to peptide epitopes, because their binding is often hindered bytheglycans [4] .
Cancercells,especiallyadenocarcinomas,expressaberrant formsandamountsofmucins [5] [6] [7] .Theexpressionofdistinct exposedoligosaccharidestructuresconfersontumorcellsan enormousrangeofpotentialligandsforinteractionwithother receptors at the cell surface [8, 9] . An increased and often depolarized expression throughout the entire cell cytoplasm has been recorded [10] . It is generally believed that MUC1 overexpressionbytumorcellsfacilitatesinvasivegrowthand metastasis [11, 12] .Itwasalsothoughtthatoverexpressionof MUC1 disrupts cell-cell and cell-extracellular matrix adhesions [13] [14] [15] .
Inaddition,MUC1wasshowntocontributetocancercell escape from immune surveillance as MUC1-expressing cells arelesssusceptibletoTcell-andNKcell-mediatedlysis [16] . On the other hand, absence of MUC1 expression also occurred and was associated with the absence of estrogen receptors (ERs) and progesterone receptors (PRs) in several breastcancerstudies.Thesefindingssupporttheobservation by Luna-More et al. [17] that tumors of the human breast negativeforMUC1arehigh-grade,areERandPRnegative andassociatedwithpositiveaxillarylymphnodes.Otherstudies also related low or negative MUC1 expression to higher tumorgradeandpoorprognosis [18, 19] .
PankoMab is a novel antibody that binds specifically to tumor MUC1. Therefore, the aim of this study was, firstly, toevaluatethenewmAb,PankoMab,asadiagnostictoolin ductalinvasivebreastcancer,secondly,tocomparethisantibodywiththeestablishedantibodiesDF3andVU-4-H5and, thirdly,tocorrelateallthesethreeantibodieswithprognostic parameters(lymphnodeinvolvement,grading,andhormone receptorexpression).
Patients and Methods
Patients Ductalbreastcarcinomaswereobtainedfrom82patientsandclassified according to current international standards. Tumor, node, metastasis (TNM) classification was done according to the World Health Organization (WHO) system [20] . The histological grading classification was determined according to a modification of the Elston and Ellis grading proposed by Bloom and Richardson [21] . The hormone receptor status wasdeterminedbyimmunohistochemistryonparaffin-embeddedmaterial.Theimmunoreactivescore(IRS)wasassignedaccordingtoRemmele andStegner [22] .Cellswereregardedashormonereceptorpositivewhen therewasapositivestainingin≥10%ofthetumorcellnuclei(table1, seeonlinesupplementalmaterial).
Immunohistochemistry
Immunohistochemistry was performed using a combination of pressure cookerheatingandthestandardstreptavidin-biotin-peroxidasecomplex withtheuseofthemouseIgG-VectastainEliteABCkit(VectorLaboratories,Burlingame,CA,USA).ThemousemAbsusedfortheseexperimentsarelistedintable2.
Paraffin-embedded tissue sections were dewaxed using xylol for 15 min,rehydratedinadescendingseriesofalcohol(100,96and70%),and subjected to epitope retrieval for 10 min in a pressure cooker using sodium citrate buffer (pH 6.0) containing 0.1 M citric acid and 0.1 M sodiumcitrateindistilledwater.Aftercooling,sectionswerewashedtwice in PBS. Endogenous peroxidase activity was blocked by immersion in 3% hydrogen peroxide (Merck, Darmstadt, Germany) in methanol for 20 min. Non-specific binding of the primary antibodies was blocked by incubating the sections with diluted normal serum (10 ml PBS containing 150 µl horse serum; Vector Laboratories) for 20 min at room temperature.Thesectionswerethenincubatedatroomtemperaturefor60 min with the primary antibodies. After washing with PBS, the sections were incubated in diluted biotinylated serum (10 ml PBS containing 50 µl horse serum; Vector Laboratories) for 30 min at room temperature. Afterincubationwiththeavidin-biotin-peroxidasecomplex(dilutedin10 mlPBS;VectorLaboratories)for30minandrepeatedwashingstepswith PBS, visualization was performed with substrate and the chromogenic compound3,3'-diaminobenzidine(DAB;Dako,Glostrup,Denmark)for 8-10min.SectionswerecounterstainedwithMayer'sacidichematoxylin anddehydratedinanascendingseriesofalcohol(70-100% Forspecificitycontrol,MUC1antibodieswereincubatedwith300U/ mlMUC1-positivecontrolreagent(Tosoh,Tokyo,Japan)andappliedto thebreastcancertissueslides.ReducedMUC1staininginfig.1bwasob-servedforDF3(CA15-3)andVU-4-H5.PankoMabishighlyspecificfor non-shedMUC1.PankoMabstainingcannotbereducedwiththeTosoh controlreagent,whichrepresentsasolubleandshedformoftheMUC1 antigen( fig.1) .
Immunohistochemical staining was performed using an appropriate positivecontrol.Positivecellsshowedabrownishcolor,andnegativecontrols,aswellasunstainedcells,wereblue.
Theintensityanddistributionpatternsofspecificimmunohistochemicalstainingwereevaluatedusingthesemi-quantitativeassayasdescribed elsewhere, and used to assess the expression pattern of various marker moleculeslikesteroidreceptors,glycodelinandMUC1 [23] [24] [25] .TheIRS score was calculated by multiplication of the optical staining intensity (gradedas0=no,1=weak,2=moderateand3=strongstaining)andthe percentageofpositivelystainedcells(0=nostaining,1=<10%ofcells, 2=11-50%ofcells,3=51-80%ofcellsand4=>81%ofcellsstained). Theslideswereexaminedbytwoindependentobservers.Sectionswere examined using a CCD color camera (JVC, Victor Company of Japan, Japan)andaLeitz(Wetzlar,Germany)microscope.
Statistics
CorrelationbetweenMUC1-antibodyinteractionwithcommonriskfactors -grading, lymph node involvement and hormone receptor status -was analyzed by using a general linear model (GLM). A multivariate logistic regression was used to analyze the correlation between MUC1 and VU-4-H5 simultaneously. The age of the patients was included in themodelascovariate.Forthispurpose,threeriskgroupsweredefined, basedontumorgradingandhormonereceptorstatus.Thelow-riskgroup comprisedgrading1or2(G1/G2)andpositivereceptorstatus.Thehighriskgroupincludedgrading3(G3)andnegativereceptorstatus.TheintermediateriskwasdefinedbyG3andpositivereceptorstatusorG1/G2 withnegativereceptorstatus.AllanalyseswereperformedbyusingSAS statisticalsoftwareV8.2.
Results

Thestainingresultsintheductalbreastcarcinomasofall82 patientsareshownintable1.
PankoMab
Expression of MUC1 as analyzed with the PankoMab antibody (n = 82, all analyzable) was down-regulated with increased grading. Highest values were measured in G1 and lowestinG3tumors,althoughwithoutstatisticalsignificance. Inaddition,therewerenodifferencesinMUC1stainingwith thePankoMabantibodyininvasiveductalcarcinomaswithor withoutlymphnodemetastasis.
However, significant differences in MUC1 staining were found in ER-positive and -negative ductal carcinomas. ERnegativecarcinomasshowedsignificantlyreducedstainingof MUC1( fig.2a;p=0 .0047)comparedtoER-positivecarcinomas( fig.2b) .Aquantitativesummaryofthestainingresults ispresentedinfig.2c.Theresultsoflinearregressionusinga GLMareshownintable3.
DF3
Although the investigation of MUC1 staining with the DF3 antibody(n=81;1notanalyzable)showednosignificantcorrelation with any of the three prognostic parameters (table  3) ,wewereabletodetectsignificantdifferencesinonesubgroup.Invasiveductalcarcinomaswithlymphnodemetastasis andlackofexpressionofERrevealedsignificantdifferences (p=0.046)inDF3staininginG2comparedtoG3tumors.G2 tumorsshowedverystrongexpressionofMUC1( fig.3a) and G3 tumors showed only weak expression of MUC1 ( fig. 3b) when analyzed with the antibody DF3. A quantitative summaryofthisstainingresultispresentedinfig3c.Theresults oflinearregressionareshownintable3.
VU-4-H5
Using the VU-4-H5 antibody (n = 79; 3 not analyzable), we coulddemonstrateasignificantcorrelationwithlymphnode involvementandgrading,butnotwiththereceptorstatus,by comparingallcases(table3).Inaddition,wealsofoundsignificantdifferencesinonespecificsubgroup.Inductalcarcinomas without lymph node metastasis and no expression of ER, VU-4-H5 staining in G2 tumors was significantly lower ( fig.4a)comparedtoG3(fig.4b )tumors(p=0.008).Inaddition,inductalcarcinomaswithlymphnodemetastasisandexpressionofER,increasedVU-4-H5stainingfromG2( fig.4c)  toG3(fig.4d )tumorswasobserved,withoutreachingstatistical significance. In contrast to PankoMab and DF3 staining, VU-4-H5 staining was increased from G1 to G3 carcinomas 
Discussion
In this study, we investigated a novel anti-MUC1 antibody calledPankoMabasapotentialnewdiagnostictoolandcompared its ability to define prognostically relevant groups of patientswithtwoestablishedantibodies(DF3andVU-4-H5) nominallydirectedagainstthesameantigen.Indetail,weexaminedtherelationshipbetweenMUC1expressionpatterns asseenbythethreeantibodiesininvasiveductalcarcinoma ofthebreastandestablishedtumorcharacteristicslikelymph nodeinvolvement,hormonereceptorstatus,andgrading.To avoid ambiguous results due to the heterogeneity of breast cancer, we focused on invasive ductal carcinomas, the most commontypeofbreastcancer. Allthreeanti-MUC1antibodieswereofthesameisotype (mouseIgG1).TheantibodyDF3wasfirstdescribedin1984 by Kufe et al. [38] . It was generated with a membrane fraction of breast cancer tissue as immunogen. DF3 is part of the CA15-3 sandwich assay for serum MUC1 [26] . The antibodyVU-4-H5wasgeneratedwithasyntheticMUC1pep-tideconsistingofthreetandemrepeatsasimmunogen.Both antibodies, DF3 and VU-4-H5, were evaluated during the ISOBMTD-4InternationalWorkshoponMonoclonalAnti-bodiesagainstMUC1 [27] .AsaresultofthisWorkshop,they were confirmed in their MUC1 specificity, and the epitope sequence was determined as APDTRPAP for both antibodies. Nonetheless, the fine specificities were not identical. In immunohistochemistry, DF3 did react with normal gastrointestinalandbreasttissueswithoutpretreatmentwhereasVU-4-H5 became positive with normal tissues only after partial deglycosylationbyperiodateoxidation.Inaddition,thecellularlocalizationoftheantigenanalyzedwithaMUC1-positive tumorcelllinewasdifferent [4] .Besidesaberrantexpression offullyglycosylatedMUC1,expressionofunderglycosylated MUC1isoftenfoundinhumancarcinomas [28] [29] [30] ;VU-4-H5 isdirectedagainstthecorepeptideofMUC1andstainsposi-tiveonlywhentheMUC1moleculeisunderglycosylated,presentingsimplerandfewercarbohydratechains [12, 31] .
PankoMab [32] is a novel MUC1 antibody explicitly tailored to recognize a tumor-associated MUC1 epitope (TA-MUC1) described earlier [33, 34] . This epitope consists of a special carbohydrate-induced conformation of the PDTRP motif. PankoMab has improved tumor selectivity, making it veryattractiveasapotentialtherapeuticantibody.
Inthepresentstudy,wedemonstratethatPankoMabmay alsobesuitedasadiagnosticantibody.Incontrasttotheantibodies DF3 and VU-4-H5, PankoMab reactivity revealed a strong correlation with the expression of the ER. No correlation to lymph node involvement was found; however, in our study, the localization of the antigen (membrane versus cytoplasm)wasnotconsidered [17] .DF3showednocorrela-tionwithgrading,lymphnodeinvolvementorERexpression. Only in one subgroup of lymph node-positive, ER-negative tumors, we found significantly reduced DF3 staining in G3 comparedtoG2tumors.VU-4-H5showedincreasedstaining intensityincorrelationwithincreasedgradingandlymphnode involvement, a result in contrast to the data of Luna-More [17] ,whichwereobtainedwithanotheranti-MUC1antibody (E29)andconsideredthecellulardistributionoftheantigen. BecauseVU-4-H5detectsMUC1withlessglycosylatedsugar chains and as glycosylation of mucins is often reduced with tumor progression [35] [36] [37] , our results on VU-4-H5 staining areinconcordancewiththesefindings.
In conclusion, PankoMab is a novel anti-MUC1 antibody withdiagnosticpotentialprovidingstrongcorrelationwithER expression,apropertynotshownbythetwoestablishedantiMUC1antibodiesusedforcomparison.Itsuseincombination with VU-4-H5 may be an alternative option in comparison withtheestablishedDF3antibody,whichshowednocorrelationwithgradingorhormonereceptorstatus. 
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